Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target?

Overview

Journal Int J Biol Sci

Specialty Biology

Date 2015 Dec 19

PMID 26681918

Citations 68

Authors

Wen Zhang

Shao-Lin Zhang

Xiaohui Hu

Kin Yip Tam

Affiliations

Soon will be listed here.

Abstract

Cancer remains a lethal threat to global lives. Development of novel anticancer therapeutics is still a challenge to scientists in the field of biomedicine. In cancer cells, the metabolic features are significantly different from those of normal ones, which are hallmarks of several malignancies. Recent studies brought atypical cellular metabolism, such as aerobic glycolysis or the Warburg effect, into the scientific limelight. Targeting these altered metabolic pathways in cancer cells presents a promising therapeutic strategy. Pyruvate dehydrogenase kinases (PDKs), key enzymes in the pathway of glucose metabolism, could inactivate the pyruvate dehydrogenase complex (PDC) by phosphorylating it and preserving the substrates pyruvate, lactate and alanine for gluconeogenesis. Overexpression of PDKs could block the oxidative decarboxylation of pyruvate to satisfy high oxygen demand in cancer cells, while inhibition of PDKs could upregulate the activity of PDC and rectify the balance between the demand and supply of oxygen, which could lead to cancer cell death. Thus, inhibitors targeting PDKs represent a promising strategy for cancer treatment by acting on glycolytic tumors while showing minimal side effects on the oxidative healthy organs. This review considers the role of PDKs as regulator of PDC that catalyzes the oxidative decarboxylation of pyruvate in mitochondrion. It is concluded that PDKs are solid therapeutic targets. Inhibition of PDKs could be an attractive therapeutic approach for the development of anti-cancer drugs.

Citing Articles

ATP deficiency triggers ganoderic acids accumulation via fatty acid β-oxidation pathway in Ganoderma lucidum.

Liu W, Sun Y, Yue S, Kong Y, Cong Q, Lan Y Microb Cell Fact. 2025; 24(1):62.

PMID: 40069729 PMC: 11900599. DOI: 10.1186/s12934-025-02668-2.

Metabolomics-driven approaches for identifying therapeutic targets in drug discovery.

Pan S, Yin L, Liu J, Tong J, Wang Z, Zhao J MedComm (2020). 2024; 5(11):e792.

PMID: 39534557 PMC: 11555024. DOI: 10.1002/mco2.792.

Combining Photodynamic Therapy and Targeted Drug Delivery Systems: Enhancing Mitochondrial Toxicity for Improved Cancer Outcomes.

Merlin J, Crous A, Abrahamse H Int J Mol Sci. 2024; 25(19).

PMID: 39409125 PMC: 11477455. DOI: 10.3390/ijms251910796.

Mitochondria: a new intervention target for tumor invasion and metastasis.

Zhou Q, Cao T, Li F, Zhang M, Li X, Zhao H Mol Med. 2024; 30(1):129.

PMID: 39179991 PMC: 11344364. DOI: 10.1186/s10020-024-00899-4.

Metabolic specialization drives reduced pathogenicity in Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Pedersen B, Simoes F, Pogrebnyakov I, Welch M, Krogh Johansen H, Molin S PLoS Biol. 2024; 22(8):e3002781.

PMID: 39178315 PMC: 11376529. DOI: 10.1371/journal.pbio.3002781.

References

Contractor T, Harris C . p53 negatively regulates transcription of the pyruvate dehydrogenase kinase Pdk2. Cancer Res. 2011; 72(2):560-7. DOI: 10.1158/0008-5472.CAN-11-1215. View

Shakya A, Cooksey R, Cox J, Wang V, McClain D, Tantin D . Oct1 loss of function induces a coordinate metabolic shift that opposes tumorigenicity. Nat Cell Biol. 2009; 11(3):320-7. DOI: 10.1038/ncb1840. View

Wu P, Peters J, Harris R . Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor alpha. Biochem Biophys Res Commun. 2001; 287(2):391-6. DOI: 10.1006/bbrc.2001.5608. View

Denko N, Fontana L, Hudson K, Sutphin P, Raychaudhuri S, Altman R . Investigating hypoxic tumor physiology through gene expression patterns. Oncogene. 2003; 22(37):5907-14. DOI: 10.1038/sj.onc.1206703. View

Lu C, Lin S, Chien C, Lin S, Lee C, Lin B . Overexpression of pyruvate dehydrogenase kinase 3 increases drug resistance and early recurrence in colon cancer. Am J Pathol. 2011; 179(3):1405-14. PMC: 3157210. DOI: 10.1016/j.ajpath.2011.05.050. View

Li Z, Van Calcar S, Qu C, Cavenee W, Zhang M, Ren B . A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A. 2003; 100(14):8164-9. PMC: 166200. DOI: 10.1073/pnas.1332764100. View

Holness M, Zariwala G, Walker C, Sugden M . Adipocyte pyruvate dehydrogenase kinase 4 expression is associated with augmented PPARγ upregulation in early-life programming of later obesity. FEBS Open Bio. 2013; 2:32-6. PMC: 3642103. DOI: 10.1016/j.fob.2012.02.003. View

Almeida R, Almeida J, Shoshkes M, Mendes N, Mesquita P, Silva E . OCT-1 is over-expressed in intestinal metaplasia and intestinal gastric carcinomas and binds to, but does not transactivate, CDX2 in gastric cells. J Pathol. 2005; 207(4):396-401. DOI: 10.1002/path.1861. View

Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

10.

Dhar S, Lippard S . Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. Proc Natl Acad Sci U S A. 2009; 106(52):22199-204. PMC: 2799774. DOI: 10.1073/pnas.0912276106. View

11.

Morrell J, Orme J, Butlin R, Roche T, Mayers R, Kilgour E . AZD7545 is a selective inhibitor of pyruvate dehydrogenase kinase 2. Biochem Soc Trans. 2003; 31(Pt 6):1168-70. DOI: 10.1042/bst0311168. View

12.

Velpula K, Bhasin A, Asuthkar S, Tsung A . Combined targeting of PDK1 and EGFR triggers regression of glioblastoma by reversing the Warburg effect. Cancer Res. 2013; 73(24):7277-89. DOI: 10.1158/0008-5472.CAN-13-1868. View

13.

Bonnet S, Archer S, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R . A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007; 11(1):37-51. DOI: 10.1016/j.ccr.2006.10.020. View

14.

Blouin J, Penot G, Collinet M, Nacfer M, Forest C, Laurent-Puig P . Butyrate elicits a metabolic switch in human colon cancer cells by targeting the pyruvate dehydrogenase complex. Int J Cancer. 2010; 128(11):2591-601. DOI: 10.1002/ijc.25599. View

15.

Yount E, Felten S, OConnor B, PETERSON R, Powell R, Yum M . Comparison of the metabolic and toxic effects of 2-chloropropionate and dichloroacetate. J Pharmacol Exp Ther. 1982; 222(2):501-8. View

16.

Yu X, Hiromasa Y, Tsen H, Stoops J, Roche T, Zhou Z . Structures of the human pyruvate dehydrogenase complex cores: a highly conserved catalytic center with flexible N-terminal domains. Structure. 2008; 16(1):104-14. PMC: 4807695. DOI: 10.1016/j.str.2007.10.024. View

17.

Kukimoto-Niino M, Tokmakov A, Terada T, Ohbayashi N, Fujimoto T, Gomi S . Inhibitor-bound structures of human pyruvate dehydrogenase kinase 4. Acta Crystallogr D Biol Crystallogr. 2011; 67(Pt 9):763-73. DOI: 10.1107/S090744491102405X. View

18.

Lombardo L, Lee F, Chen P, Norris D, Barrish J, Behnia K . Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004; 47(27):6658-61. DOI: 10.1021/jm049486a. View

19.

Kluza J, Corazao-Rozas P, Touil Y, Jendoubi M, Maire C, Guerreschi P . Inactivation of the HIF-1α/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants. Cancer Res. 2012; 72(19):5035-47. DOI: 10.1158/0008-5472.CAN-12-0979. View

20.

Cairns R, Harris I, Mak T . Regulation of cancer cell metabolism. Nat Rev Cancer. 2011; 11(2):85-95. DOI: 10.1038/nrc2981. View